DGAP-News: Viridax Corporation Licenses Critical Rights
(firmenpresse) - Viridax Corporation / Key word(s): Miscellaneous
04.11.2010 08:30
---------------------------------------------------------------------------
Viridax Corporation Licenses Critical Rights
November 4, 2010 - Viridax Corporation (FSE:VRC) ('Viridax' or the
'Company') is pleased to report that on October 28th, 2010 the Company
entered into a licensing agreement with Richard Honour, PhD and Richard
Herman, PhD, two of the leading experts in the development of
genetically-selected versions of naturally-occurring viruses, called
bacteriophage. Bacteriophage are viruses that are specifically developed
for the purpose of parasitizing and killing bacteria and thereby providing
effective treatment for diseases characterized by the presence of
antibiotic-resistant bacteria, such as staph infections and tuberculosis.
The licensing agreement allows the Company to commercially exploit certain
patents pending before the U.S. Patent Office that are critically important
to the execution of the Company's business plan and provide the foundation
upon which the Company will be built going forward.
About Viridax Corporation
Viridax Corporation was formed to develop new products for the treatment of
respiratory and systemic infections incited by Staphylococcus aureus (S.
aureus) and other Staphylococcal species. The management of Viridax is
primarily focused on providing safe, effective and affordable treatment
alternatives to conventional antibiotics, and to demonstrate the clinical
utility of the Viridax products by substantially reducing the incidence,
prevalence, morbidity and mortality of targeted bacterial infections in
both community and hospital settings. The Company plans to develop products
that are less toxic and more efficacious than conventional antibiotics, and
at lower cost, but that will target antibiotic-resistant bacteria, thus
providing access to extensive global markets. Management intends to
manufacture and evaluate the initial S. aureus bacteriophage product in
compliance with US Food and Drug Administration (FDA) guidelines to assure
approval by US and international regulatory authorities.
On behalf of the Board of Directors
Viridax Corporation
Richard C. Honour, PhD.
Vice-President, Research and Development
Tel. (425) 772-1473
Email: rhono(at)viridax.com
Website: www.viridax.com
FORWARD-LOOKING STATEMENTS
Statements in this document which are not purely historical are
'forward-looking statements', including any statements regarding the
intent, belief or current expectations of Viridax Corporation and members
of its management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that such forward-looking
statements are not guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from those
contemplated by such forward-looking statements. Important factors
currently known to management that could cause actual results to differ
materially from those in forward-looking statements include, among others,
material changes in the global capital markets that may impact negatively
on the Company's ability to secure the working capital required to complete
the development and production of its pharmaceutical products on a timely
basis, the competitive nature of the biopharmaceutical industry and the
ability of the Company to attract the personnel required to efficiently
execute the Company's business plan. Forward looking statements are made
based on management's beliefs, estimates and opinions on the date the
statements are made and the Company undertakes no obligation to update
forward-looking statements if these beliefs, estimates and opinions or
other circumstances should change, except as updates may be required by
applicable law. Such forward-looking statements reflect our current views
with respect to future events and are subject to certain risks,
uncertainties and assumptions, including, the risks and uncertainties
outlined in our most recent financial statements. Although the Company
believes that the plans, expectations and intentions contained in this news
release are reasonable, there can be no assurance those plans, expectations
or intentions will prove to be accurate. Investors should consider all of
the information set forth herein. This news release shall not constitute an
offer to sell or the solicitation of an offer to buy securities nor shall
there be any sale of securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to qualification under the
applicable securities laws of any such jurisdiction.
04.11.2010 08:30 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Datum: 04.11.2010 - 08:30 Uhr
Sprache: Deutsch
News-ID 32489
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 179 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Viridax Corporation Licenses Critical Rights"
steht unter der journalistisch-redaktionellen Verantwortung von
Viridax Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
